Intratumoral TNFα improves immunotherapy

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1395-1397

  Johansson, Anna ^a   Hamzah, Juliana ^b   Ganss, Ruth ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immune therapy; Stroma reprogramming; Vessel remodeling

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

BLOOD VESSEL PERMEABILITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CARCINOGENESIS; CELL DEATH; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; FIBROBLAST; IMMUNOMODULATION; IMMUNOSTIMULATION; LOW DRUG DOSE; MACROPHAGE; NONHUMAN; NOTE; OVERALL SURVIVAL; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROMOTER REGION; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84886945457     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20981     Document Type: Note

References (10)

1. Johansson A, Ganss R. Remodeling of tumor stroma and response to therapy. Cancers 2012; 4:340-53; http://dx.doi.org/10.3390/cancers4020340.
2. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, et al. Vascular normalization in Rgs5- deficient tumours promotes immune destruction. Nature 2008; 453:410-4; PMID:18418378; http://dx.doi.org/10.1038/nature06868.
3. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011; 19:31-44; PMID:21215706; http://dx.doi.org/10.1016/j.ccr.2010.11.009.
4. Ganss R, Ryschich E, Klar E, Arnold B, Hämmerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002; 62:1462-70; PMID:11888921.
5. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002; 110:475-82; PMID:12189241.
6. van Laarhoven HW, Gambarota G, Heerschap A, Lok J, Verhagen I, Corti A, et al. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drugs 2006; 24:27-36; PMID:16379040; http://dx.doi.org/10.1007/s10637-005-4540-2.
7. Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, et al. Targeting TNFα to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 2012; 188:2687-94; PMID:22323546; http://dx.doi.org/10.4049/jimmunol.1101877.
8. Johansson A, Hamzah J, Payne CJ, Ganss RT. Tumortargeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci USA 2012; 109:7841-6; PMID:22547817; http://dx.doi.org/10.1073/pnas.1118296109.
9. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171-80; PMID:20631075; http://dx.doi.org/10.1158/0008-5472.CAN-10-0153.
10. + T-cell immunotherapy. Immunol Cell Biol 2006; 84:383-9; PMID:16834573; http://dx.doi.org/10.1111/j.1440-1711.2006.01448.x.